Changeflow GovPing Consumer Protection Mavera AB Fined SEK 14.3M for Dominant Position...
Priority review Enforcement Added Final

Mavera AB Fined SEK 14.3M for Dominant Position Abuse

Favicon for www.konkurrensverket.se Sweden Konkurrensverket
Filed
Detected
Email

Summary

The Swedish Competition Authority fined Mavera AB SEK 14.3 million for abusing a dominant position in the market for insurance medical advisory services since at least 2020. The Authority also ordered Mavera to cease applying exclusivity agreements that prevented insurance medical advisers from taking assignments from competing intermediary services, with a conditional fine of SEK 30 million for non-compliance. The decision may be appealed to the Swedish Patent and Market Court.

“The Swedish Competition Authority has today decided that the company Mavera AB is to pay an administrative fine of just over SEK 14 million for abuse of a dominant position.”

KKV , verbatim from source
Why this matters

Firms providing intermediary services in Sweden should audit their adviser contracts for exclusivity clauses that could foreclose competitors from accessing specialist service providers. The conditional SEK 30 million penalty for non-compliance with the cease order underscores that exclusivity arrangements in markets where a company holds dominant position carry significant enforcement risk.

AI-drafted from the source document, validated against GovPing's analyst note standards . For the primary regulatory language, read the source document .
Published by KKV on konkurrensverket.se . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors Sweden Konkurrensverket for new consumer protection regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 3 changes logged to date.

What changed

The Swedish Competition Authority issued a final decision finding that Mavera AB abused its dominant position in the market for insurance medical advisory services by applying exclusivity clauses in contracts with medical advisers since at least 2020. The Authority imposed an administrative fine of SEK 14.3 million and ordered Mavera to immediately cease the exclusivity conduct, subject to a conditional fine of SEK 30 million for non-compliance.\n\nCompanies holding dominant positions in Sweden should review their contract terms to ensure exclusivity provisions do not unlawfully restrict competition. Competitors and new market entrants who were prevented from engaging medical advisers by exclusivity agreements may have been harmed by this conduct.

Penalties

SEK 14.3 million administrative fine; conditional fine of SEK 30 million for non-compliance with the cease order

Archived snapshot

Apr 22, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Intermediary of insurance medical advice fined and prohibited from applying exclusivity agreements

The Swedish Competition Authority has today decided that the company Mavera AB is to pay an administrative fine of just over SEK 14 million for abuse of a dominant position. At the same time, the Authority orders Mavera to cease applying exclusivity agreements that prevent the insurance medical advisers engaged by the company from taking assignments from competing intermediary services.

Mavera AB provides insurance medical assessments carried out by specialised advisers. Mavera’s clients include, for example, insurance companies, claims management companies and public authorities. The purpose of obtaining an insurance medical assessment may include determining whether personal injuries are covered by an insurance policy. The insurance medical advisers are doctors active in various medical specialist fields. The Swedish Competition Authority finds that Mavera has held a dominant position on the market for the intermediation of insurance medical advisory services since at least 2020.

For several years, Mavera was the sole provider of such services in Sweden. When a competing service was introduced in 2020, Mavera responded by introducing provisions in its contracts with insurance medical advisers that prevented the advisers from accepting assignments from the company’s competitors. According to the Authority’s investigation, these exclusivity clauses have hindered market entry and expansion in a manner constituting an abuse of Mavera’s dominant position.

Within several medical specialist fields, Mavera has exclusivity agreements with all, or almost all, available advisers. This means that competitors are unable to engage these insurance medical advisers and therefore risk of being excluded from the market. The conduct may also make it more difficult for new operators to enter and compete effectively in the market.

“Where a company holding a dominant position on the market uses exclusive supply agreements, this may lead to an unlawful restriction of competition. This constitutes a serious infringement of competition law, and in this case we have chosen to impose both an administrative fine and an order to bring the anticompetitive conduct to an end,” says Marie Östman, Director General of the Swedish Competition Authority.

The Swedish Competition Authority has today decided that Mavera is to pay a fine of SEK 14.3 million. As Mavera continues to apply the exclusivity clauses, the Authority also orders the company to cease this conduct. The order is subject to a conditional fine for non-compliance of SEK 30 million.

The decision of the Swedish Competition Authority may be appealed to the Swedish Patent and Market Court.

For further information, please contact:

Malin Vässblad, Competition Counsel, +46 8 700 15 36,
malin.vassblad@kkv.se

Marie Strömberg Lindvall, Press Officer, +46 8 700 15 92,
marie.stromberglindvall@kkv.se

Related link

Read the decision (in Swedish)

English summary of the decision

Last updated: 2026-03-24

Press release 19 march 2026

Parties

Get daily alerts for Sweden Konkurrensverket

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from KKV.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
KKV
Filed
March 24th, 2026
Instrument
Enforcement
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Substantive

Who this affects

Applies to
Insurers Healthcare providers
Industry sector
5241 Insurance
Activity scope
Market dominance abuse Exclusive dealing arrangements
Geographic scope
SE SE

Taxonomy

Primary area
Antitrust & Competition
Operational domain
Compliance
Topics
Healthcare

Get alerts for this source

We'll email you when Sweden Konkurrensverket publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!